Global Urinary Tract Infections Therapeutics Report 2018: Key Players Identified as Achaogen, AmpliPhi Biosciences and Iterum Therapeutics - ResearchAndMarkets.com

DUBLIN--()--The "Urinary Tract Infections Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

The study analyzed that UTIs therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.

According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate.

It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature.

The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.

The companies involved in the UTIs therapeutic pipeline are developing various drug candidates as combination therapies, that have several advantages such as, improved medication compliance by decreasing the pill burden of patients, increased efficacy, and reduced side effects and cost.

For instance, C-Scape, a Phase I drug candidate by Achaogen Inc. is a combination of ceftibuten and clavulanate, that are small molecules obtained from the synthetic source. Both ceftibuten and clavulanate act by different mechanism of action but give synergistic effects. Ceftibuten acts as cell wall synthesis inhibitor and, clavulanate acts as beta-lactamase inhibitor.

Key Players

  • Achaogen Inc.
  • AmpliPhi Biosciences Corporation
  • Iterum Therapeutics Limited

Other Notable Players

  • Rebiotix Inc.

Key Topics Covered

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. UTIs Therapeutics Pipeline Analysis by Phase (2018)

6. Clinical Trials Review

7. Competitive Landscape

8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/ndl3rz/global_urinary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Clinical Trials, Urological Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Clinical Trials, Urological Disorders Drugs